PDCD1 and neoplasm: In addition to genetic modifications, the use of PD-1 antibody checkpoint blockade, intracellular PD-1 shRNA blockade, or PD-1 dominant-negative receptor has demonstrated the ability to resist tumor-induced T-cell exhaustion and restore effector function in CAR-T cells (Cherkassky et al.2016).